Guggenheim initiated coverage of Kura Oncology (KURA) with a Neutral rating and no price target The firm expects a near-term relapsed/refractory nucleophosmin 1-mutated acute myeloid leukemia launch for the company buy says it will be difficult to drive value with Syndax (SNDX_ already on market for this smaller patient population.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology initiated with a Neutral at Guggenheim
- Optimistic Buy Rating for Kura Oncology: KO-2806’s Potential in ccRCC and Market Opportunities
- Kura Oncology’s KO-2806: A Promising Investment with $1.5 Billion Market Potential in RCC
- Kura Oncology’s Earnings Call: Progress Amidst Challenges
- Kura Oncology price target lowered to $24 from $28 at Citizens JMP